Developer docs
API playgroundTry for free, no card

Search company profiles

Spermosens

Full company profile

uuid0002c3j

Namestring
Spermosens
Legal namestring
Spermosens AB (publ)
Websiteurl
spermosens.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Spermosens AB (publ) is a Swedish medical device company headquartered at Medicon Village in Lund, founded in 2018 and listed on Spotlight Stock Market in Stockholm since 5 May 2021 (ticker SPERM; also tradable on Frankfurt as 9R5). The company develops JUNO-Checked, a patented diagnostic platform that measures sperm cells' functional ability to bind to the JUNO protein on human egg cells — a step in fertilization not captured by conventional semen analysis. The system combines a reusable electrochemical measurement instrument with disposable single-use biosensor chips onto which a semen sample is applied, and outputs a proprietary 'JUNO Score' intended to predict fertilization potential and guide the choice between standard IVF and ICSI. Generation 3 of the platform, designed for high-volume clinical workflows and laboratory-platform compatibility, was completed in April 2026 and is currently undergoing clinical validation at the Reproductive Medicine Center in Malmö; a prior study at the same site established a statistically significant correlation between the JUNO Score and IVF fertilization rate.

Spermosens operates a partner-driven commercialization model rather than building its own global salesforce. Future monetization is expected through licensing royalties from established Assisted Reproductive Technology market players, supported by direct research-use sales (e.g., Seattle Sperm Bank) as a stepping stone and clinical validation collaborations with leading IVF clinics. Memoranda of Understanding with Sapyen and RSI Technology Group, partnerships with Scalania AG (Europe) and ScanMed Partners (United States), and active discussions with a leading Japanese ART company structure the global rollout across Europe, the United States, Japan, and Australia. The intellectual property portfolio is protected by European Patent EP 3 768 825 (valid to 2039) with national grants in Hong Kong, Canada, Mexico, Israel, and China during 2025 and pending applications in additional jurisdictions. The company is ISO 13485:2016 compliant and is pursuing CE marking for JUNO-Checked.

As of year-end 2025 the company reported an operating loss of SEK 9.2 million (versus SEK 9.16 million in 2024) and SEK 6.8 million in cash, with no product revenue disclosed. It is led by CEO Tore Duvold, CSO Maria Liljander, CFO Alexander Dahlqvist, and Chairman Ulrik Spork; the Advisory Board includes Professors Aleksander Giwercman, Trine B. Haugen, Emir Henic, and Claus Yding Andersen. Total headcount is reported as 1–10 employees.

Short descriptiontext

Spermosens AB is a Swedish medical device company developing JUNO-Checked, a patented biosensor diagnostic that measures sperm-egg binding via recombinant JUNO protein to predict IVF fertilization potential. It serves IVF clinics and sperm banks, pursuing commercialization through licensing partnerships across Europe, the United States, Japan, and Australia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
male fertility diagnostics, sperm binding biosensor, IVF treatment selection, assisted reproductive technology, JUNO receptor assay
Industry3 codes
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAKAJAC
Reproductive Endocrinology & Infertility (IVF/Fertility)
SECONDARYHLALAHAK
Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling)
Healthcare & Life Sciences/Telehealth Platforms/Women’s & Family Health Telehealth Platforms (fertility, pregnancy, pediatrics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Testing Laboratories8734
Product category
Reproductive Medicine Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing royalties (planned)
TypeLicensing Royalties
Description

Future licensing income from commercial partners is expected to drive Spermosens to cash flow positivity; the SEK 10.8 million funding round in March 2025 is intended to bridge the company to this inflection point by enabling technology optimization and partnership signings.

news.cision.com
2Research-use sales of JUNO-Checked
TypeHardware Sales
Description

Early-stage sales of the device for research purposes to specialist accounts such as sperm banks (e.g., Seattle Sperm Bank) as a stepping stone toward broader commercial acceleration prior to full product launch.

spermosens.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1JUNO-Checked
Description

Patented, proprietary male fertility diagnostic system that measures sperm cells' ability to bind to the JUNO receptor on the egg, providing a functional assessment of fertilization capacity to assist clinicians in choosing between standard IVF or ICSI treatment.

spermosens.com
Core offering1 text field

Spermosens develops and manufactures JUNO-Checked, a patented diagnostic medical device platform that predicts sperm fertilization capacity by measuring the ability of sperm cells to bind to the recombinant JUNO egg-cell protein. The system pairs a reusable electrochemical measuring instrument with disposable single-use biosensor chips onto which the semen sample is applied, and outputs a quantitative "JUNO Score" intended to help clinicians and embryologists decide between standard IVF and ICSI treatment. The product is sold for research use to specialist accounts and is being commercialized globally via licensing agreements with ART market partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Statistically significant positive correlation between JUNO Score and IVF fertilization rate (percentage of MII oocytes developing into 2PN zygotes)
+3 more records
Product overview1 text field

Spermosens offers a single core product platform, JUNO-Checked, a world-first automated male fertility diagnostic medical device that assesses sperm binding capacity to the egg-cell JUNO protein to direct clinicians toward the appropriate IVF treatment (standard-IVF vs ICSI). The offering is a platform-plus-consumable architecture: the reusable measuring instrument with proprietary software analyzes single-use electrochemical biosensor chips to which semen samples are applied. The latest iteration, JUNO-Checked Generation 3, is the commercially adapted version targeting higher throughput, faster analysis, and routine laboratory compatibility, currently undergoing clinical validation at the Reproductive Medicine Center (RMC) in Malmö ahead of commercialization via licensing and partnership agreements across Europe, the US, Japan, and Australia.

Product and service3 records
1JUNO-Checked
CategoryCore diagnostic product (medical device)
Description

Patented, user-friendly, rapid, small-footprint diagnostic system that predicts sperm fertilization capacity by measuring sperm binding to the egg-cell JUNO protein via recombinant JUNO exposure. Outputs a quantitative "JUNO Score" intended to assist clinicians and embryologists in deciding between standard IVF and ICSI treatment, and to reduce conventional IVF treatment iterations.

2JUNO-Checked Generation 3
CategoryLatest product version (third generation)
Description

Third-generation JUNO-Checked system developed to meet the performance standards necessary for a commercially viable product, with technical improvements aimed at supporting high-volume clinical workflows, faster analysis, higher throughput, and compatibility with routine laboratory platforms. Currently undergoing clinical validation at RMC Malmö.

3Single-use biosensor chips for JUNO-Checked
CategoryConsumable component
Description

Disposable electrochemical chips onto which the sperm solution is applied, used with the JUNO-Checked measuring instrument to analyze sperm binding to the egg cell as part of the JUNO-Checked system.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Memorandum of Understanding signed after the 2025 reporting period to advance partner-driven commercialization of male fertility diagnostics in global markets. The MoU positions Spermosens to leverage Sapyen's channels and capabilities for bringing JUNO-Checked to global ART market customers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Memorandum of Understanding signed after the 2025 reporting period to advance partner-driven commercialization of JUNO-Checked male fertility diagnostics globally. Targets global ART market access through RSI Technology Group's commercialization capabilities.

3Scalania AG
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Newly formed partnership expected to strengthen Spermosens' regulatory and market activities in Europe for JUNO-Checked, complementing ongoing commercial-partner discussions in Europe, the US, and Japan.

spermosens.com
4ScanMed Partners
Strategic tierCoreTypeGTM or Marketing Partner
Description

Collaboration driving business development for JUNO-Checked in the United States, in the context of Spermosens' broader active partnership discussions across the US, Europe, and Japan following positive clinical results.

spermosens.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical validation partner — RMC Malmö hosted Spermosens' statistically significant clinical study that established the correlation between JUNO Score and IVF fertilization rate (n=53 in final analysis). In April 2026, RMC Malmö initiated the Generation 3 system clinical validation study, with seven patients successfully tested to date. RMC is one of the largest IVF clinics in Sweden.

6Fram Advokatbyrå KB
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Legal advisor to Spermosens in connection with the exercise of the TO5 warrants in 2025.

spermosens.com
7HØIBERG
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

IP partner working closely with Spermosens' development team to build the patent portfolio, recognized by CSO Kushagr Punyani as a key contributor to the EPO 'Intention to Grant' notification in April 2021.

spermosens.com
Strategic tierMinorTypeOthers
Description

Spermosens holds an ESHRE Management Membership, providing engagement with the European clinical embryology and reproductive medicine community.

TypeOthers
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sweden-based global leader in IVF media, consumables and ART lab equipment. Directly comparable as a listed Swedish ART-diagnostics-and-consumables company targeting the same IVF clinic customer base that JUNO-Checked aims to serve.

TypeBroad incumbent
Description

Major fertility and women's health diagnostics and medical device company offering sperm analysis and ART lab solutions. A natural partner or competitor for male fertility diagnostics within the global IVF clinic channel.

TypeBroad incumbent
Description

Provider of precision instruments, consumables, and software for the ART and reproductive science markets. Comparable as a capital-equipment-plus-disposables seller to IVF clinics and a candidate licensing partner for JUNO-Checked.

TypeDirect peer
Description

Developer and manufacturer of ART lab instruments and consumables including sperm preparation and quality tools. Closely aligned product category, customer base (IVF clinics), and instrument-plus-chip business model to Spermosens.

TypeBroad incumbent
Description

Global supplier of cell culture media, reagents, and ART products used across IVF workflows. Comparable as a large incumbent supplying consumables and instruments to the same IVF clinic channel that Spermosens targets.

TypeEmerging player
Description

Startup developing AI-powered at-home and clinical sperm quality diagnostics. Comparable as an emerging player in male fertility diagnostics with overlapping end-customers (clinics, sperm banks, patients).

TypeEmerging player
Description

Male fertility diagnostic startup that has signed an MoU with Spermosens. Comparable as an emerging player in male fertility testing with overlapping product vision and shared go-to-market focus.

TypeEmerging player
Description

Male fertility testing and sperm analysis company offering both clinical and direct-to-consumer sperm quality diagnostics. Comparable as an emerging player addressing the same male infertility diagnostic gap.

9DxNow / Zymot (now part of CooperSurgical)
TypeDirect peer
Description

Developer of the ZyMōt microfluidic sperm preparation device — a functional sperm quality/selection tool used in IVF labs. Comparable as a sperm-function diagnostic/selection device competitor within IVF clinic workflows.

TypeEmerging player
Description

Emerging player developing sperm-sorting technologies for the ART market. Comparable as a niche player in functional male fertility technology addressing IVF laboratory workflow needs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spermosens

Reproductive Medicine Diagnosticsspermosens.com

Spermosens AB is a Swedish medical device company developing JUNO-Checked, a patented biosensor diagnostic that measures sperm-egg binding via recombinant JUNO protein to predict IVF fertilization potential. It serves IVF clinics and sperm banks, pursuing commercialization through licensing partnerships across Europe, the United States, Japan, and Australia.

What Spermosens does

Spermosens AB (publ) is a Swedish medical device company headquartered at Medicon Village in Lund, founded in 2018 and listed on Spotlight Stock Market in Stockholm since 5 May 2021 (ticker SPERM; also tradable on Frankfurt as 9R5). The company develops JUNO-Checked, a patented diagnostic platform that measures sperm cells' functional ability to bind to the JUNO protein on human egg cells — a step in fertilization not captured by conventional semen analysis. The system combines a reusable electrochemical measurement instrument with disposable single-use biosensor chips onto which a semen sample is applied, and outputs a proprietary 'JUNO Score' intended to predict fertilization potential and guide the choice between standard IVF and ICSI. Generation 3 of the platform, designed for high-volume clinical workflows and laboratory-platform compatibility, was completed in April 2026 and is currently undergoing clinical validation at the Reproductive Medicine Center in Malmö; a prior study at the same site established a statistically significant correlation between the JUNO Score and IVF fertilization rate.

Spermosens operates a partner-driven commercialization model rather than building its own global salesforce. Future monetization is expected through licensing royalties from established Assisted Reproductive Technology market players, supported by direct research-use sales (e.g., Seattle Sperm Bank) as a stepping stone and clinical validation collaborations with leading IVF clinics. Memoranda of Understanding with Sapyen and RSI Technology Group, partnerships with Scalania AG (Europe) and ScanMed Partners (United States), and active discussions with a leading Japanese ART company structure the global rollout across Europe, the United States, Japan, and Australia. The intellectual property portfolio is protected by European Patent EP 3 768 825 (valid to 2039) with national grants in Hong Kong, Canada, Mexico, Israel, and China during 2025 and pending applications in additional jurisdictions. The company is ISO 13485:2016 compliant and is pursuing CE marking for JUNO-Checked.

As of year-end 2025 the company reported an operating loss of SEK 9.2 million (versus SEK 9.16 million in 2024) and SEK 6.8 million in cash, with no product revenue disclosed. It is led by CEO Tore Duvold, CSO Maria Liljander, CFO Alexander Dahlqvist, and Chairman Ulrik Spork; the Advisory Board includes Professors Aleksander Giwercman, Trine B. Haugen, Emir Henic, and Claus Yding Andersen. Total headcount is reported as 1–10 employees.

Spermosens firmographics

Firmographics
Name
Spermosens
Legal name
Spermosens AB (publ)
Website
https://spermosens.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Spermosens AB is a Swedish medical device company developing JUNO-Checked, a patented biosensor diagnostic that measures sperm-egg binding via recombinant JUNO protein to predict IVF fertilization potential. It serves IVF clinics and sperm banks, pursuing commercialization through licensing partnerships across Europe, the United States, Japan, and Australia.
Ownership category
akta.pro rank

Spermosens industry classification

Industry
Product category
Reproductive Medicine Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAKAJAC
Reproductive Endocrinology & Infertility (IVF/Fertility)
SECONDARYHLALAHAK
Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling)
Healthcare & Life Sciences/Telehealth Platforms/Women’s & Family Health Telehealth Platforms (fertility, pregnancy, pediatrics)

Keywords

  • Male fertility diagnostics
  • Sperm binding biosensor
  • IVF treatment selection
  • Assisted reproductive technology
  • JUNO receptor assay

Where Spermosens is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Spermosens business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing royalties (planned): Future licensing income from commercial partners is expected to drive Spermosens to cash flow positivity; the SEK 10.8 million funding round in March 2025 is intended to bridge the company to this inflection point by enabling technology optimization and partnership signings.
  2. Research-use sales of JUNO-Checked: Early-stage sales of the device for research purposes to specialist accounts such as sperm banks (e.g., Seattle Sperm Bank) as a stepping stone toward broader commercial acceleration prior to full product launch.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Spermosens product offering

Product offering

Core offering

Spermosens develops and manufactures JUNO-Checked, a patented diagnostic medical device platform that predicts sperm fertilization capacity by measuring the ability of sperm cells to bind to the recombinant JUNO egg-cell protein. The system pairs a reusable electrochemical measuring instrument with disposable single-use biosensor chips onto which the semen sample is applied, and outputs a quantitative "JUNO Score" intended to help clinicians and embryologists decide between standard IVF and ICSI treatment. The product is sold for research use to specialist accounts and is being commercialized globally via licensing agreements with ART market partners.

Product overview

Spermosens offers a single core product platform, JUNO-Checked, a world-first automated male fertility diagnostic medical device that assesses sperm binding capacity to the egg-cell JUNO protein to direct clinicians toward the appropriate IVF treatment (standard-IVF vs ICSI). The offering is a platform-plus-consumable architecture: the reusable measuring instrument with proprietary software analyzes single-use electrochemical biosensor chips to which semen samples are applied. The latest iteration, JUNO-Checked Generation 3, is the commercially adapted version targeting higher throughput, faster analysis, and routine laboratory compatibility, currently undergoing clinical validation at the Reproductive Medicine Center (RMC) in Malmö ahead of commercialization via licensing and partnership agreements across Europe, the US, Japan, and Australia.

Differentiator

Problem solved

Functional benefit

Brands

  • JUNO-Checked: Patented, proprietary male fertility diagnostic system that measures sperm cells' ability to bind to the JUNO receptor on the egg, providing a functional assessment of fertilization capacity to assist clinicians in choosing between standard IVF or ICSI treatment.

Products and services

  • JUNO-Checked Patented, user-friendly, rapid, small-footprint diagnostic system that predicts sperm fertilization capacity by measuring sperm binding to the egg-cell JUNO protein via recombinant JUNO exposure. Outputs a quantitative "JUNO Score" intended to assist clinicians and embryologists in deciding between standard IVF and ICSI treatment, and to reduce conventional IVF treatment iterations.
  • JUNO-Checked Generation 3 Third-generation JUNO-Checked system developed to meet the performance standards necessary for a commercially viable product, with technical improvements aimed at supporting high-volume clinical workflows, faster analysis, higher throughput, and compatibility with routine laboratory platforms. Currently undergoing clinical validation at RMC Malmö.
  • Single-use biosensor chips for JUNO-Checked Disposable electrochemical chips onto which the sperm solution is applied, used with the JUNO-Checked measuring instrument to analyze sperm binding to the egg cell as part of the JUNO-Checked system.

Quantifiable outcome

  • Statistically significant positive correlation between JUNO Score and IVF fertilization rate (percentage of MII oocytes developing into 2PN zygotes)
  • +3 more outcomes

Companies that use Spermosens

Customer profile

Named customers2 records

Ideal customer profiles2 records

Spermosens technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Spermosens partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • SapyencoreStrategic or Co-development Partner · 11 February 2026Memorandum of Understanding signed after the 2025 reporting period to advance partner-driven commercialization of male fertility diagnostics in global markets. The MoU positions Spermosens to leverage Sapyen's channels and capabilities for bringing JUNO-Checked to global ART market customers.
  • RSI Technology GroupcoreStrategic or Co-development Partner · 11 February 2026Memorandum of Understanding signed after the 2025 reporting period to advance partner-driven commercialization of JUNO-Checked male fertility diagnostics globally. Targets global ART market access through RSI Technology Group's commercialization capabilities.
  • Scalania AGcoreStrategic or Co-development PartnerNewly formed partnership expected to strengthen Spermosens' regulatory and market activities in Europe for JUNO-Checked, complementing ongoing commercial-partner discussions in Europe, the US, and Japan.
  • ScanMed PartnerscoreGTM or Marketing PartnerCollaboration driving business development for JUNO-Checked in the United States, in the context of Spermosens' broader active partnership discussions across the US, Europe, and Japan following positive clinical results.
  • Reproductive Medicine Center (RMC) MalmöcoreStrategic or Co-development PartnerClinical validation partner — RMC Malmö hosted Spermosens' statistically significant clinical study that established the correlation between JUNO Score and IVF fertilization rate (n=53 in final analysis). In April 2026, RMC Malmö initiated the Generation 3 system clinical validation study, with seven patients successfully tested to date. RMC is one of the largest IVF clinics in Sweden.
  • Fram Advokatbyrå KBminorImplementation/ SI/ Consulting PartnerLegal advisor to Spermosens in connection with the exercise of the TO5 warrants in 2025.
  • HØIBERGminorImplementation/ SI/ Consulting PartnerIP partner working closely with Spermosens' development team to build the patent portfolio, recognized by CSO Kushagr Punyani as a key contributor to the EPO 'Intention to Grant' notification in April 2021.
  • ESHRE (European Society of Human Reproduction and Embryology)minorOthersSpermosens holds an ESHRE Management Membership, providing engagement with the European clinical embryology and reproductive medicine community.
  • Medicon VillageOthers

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Spermosens competitors and assessment

Company assessment

Broad incumbents

  • Vitrolife: Sweden-based global leader in IVF media, consumables and ART lab equipment. Directly comparable as a listed Swedish ART-diagnostics-and-consumables company targeting the same IVF clinic customer base that JUNO-Checked aims to serve.
  • CooperSurgical (CooperCompanies): Major fertility and women's health diagnostics and medical device company offering sperm analysis and ART lab solutions. A natural partner or competitor for male fertility diagnostics within the global IVF clinic channel.
  • Hamilton Thorne: Provider of precision instruments, consumables, and software for the ART and reproductive science markets. Comparable as a capital-equipment-plus-disposables seller to IVF clinics and a candidate licensing partner for JUNO-Checked.
  • FUJIFILM Irvine Scientific: Global supplier of cell culture media, reagents, and ART products used across IVF workflows. Comparable as a large incumbent supplying consumables and instruments to the same IVF clinic channel that Spermosens targets.

Direct peers

  • Genea Biomedx: Developer and manufacturer of ART lab instruments and consumables including sperm preparation and quality tools. Closely aligned product category, customer base (IVF clinics), and instrument-plus-chip business model to Spermosens.
  • DxNow / Zymot (now part of CooperSurgical): Developer of the ZyMōt microfluidic sperm preparation device — a functional sperm quality/selection tool used in IVF labs. Comparable as a sperm-function diagnostic/selection device competitor within IVF clinic workflows.

Emerging players

  • Mojo: Startup developing AI-powered at-home and clinical sperm quality diagnostics. Comparable as an emerging player in male fertility diagnostics with overlapping end-customers (clinics, sperm banks, patients).
  • Sapyen: Male fertility diagnostic startup that has signed an MoU with Spermosens. Comparable as an emerging player in male fertility testing with overlapping product vision and shared go-to-market focus.
  • Legacy (Reproductive): Male fertility testing and sperm analysis company offering both clinical and direct-to-consumer sperm quality diagnostics. Comparable as an emerging player addressing the same male infertility diagnostic gap.
  • Engender Technologies: Emerging player developing sperm-sorting technologies for the ART market. Comparable as a niche player in functional male fertility technology addressing IVF laboratory workflow needs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Spermosens social profiles

Digital presence

Spermosens compliance and trust

Trust signal

Compliance2 records

Spermosens financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spermosens leadership team

Management profile

Number of profiles

Profiles13 records

Spermosens funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spermosens M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spermosens

What does Spermosens do?

Spermosens develops and manufactures JUNO-Checked, a patented diagnostic medical device platform that predicts sperm fertilization capacity by measuring the ability of sperm cells to bind to the recombinant JUNO egg-cell protein. The system pairs a reusable electrochemical measuring instrument with disposable single-use biosensor chips onto which the semen sample is applied, and outputs a quantitative "JUNO Score" intended to help clinicians and embryologists decide between standard IVF and ICSI treatment. The product is sold for research use to specialist accounts and is being commercialized globally via licensing agreements with ART market partners.

Is Spermosens a public or private company?

Spermosens is a public company. It is classified as public and is currently operating.

When was Spermosens founded?

Spermosens was founded in 2018. It employs 1 to 10 people.

Where is Spermosens based?

Spermosens is headquartered in Lund, Sweden, in the Europe region.

How does Spermosens make money?

Two revenue lines are on record. Licensing royalties (planned) is the primary driver. The others are research-use sales of JUNO-Checked.

Who are Spermosens's main competitors?

Broad incumbents on record are Vitrolife, CooperSurgical (CooperCompanies), Hamilton Thorne and FUJIFILM Irvine Scientific. Direct peers are Genea Biomedx and DxNow / Zymot (now part of CooperSurgical). Emerging players are Mojo, Sapyen, Legacy (Reproductive) and Engender Technologies.

Does Spermosens have an API?

No public API is recorded for Spermosens.

What industry is Spermosens in?

Spermosens's product category is Reproductive Medicine Diagnostics. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAKAJAC, Reproductive Endocrinology & Infertility (IVF/Fertility). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comSpermosens AB (publ) to Host Live Q&A Town Hall on 19 November 2026Spermosens AB will host a live Q&A town hall on 19 November 2026 at 12:00 CET, with CEO Tore Duvold addressing questions. The session follows the Q3 2026 report and is open to all interested parties, with advance questions due by 18 November.news.cision.comSpermosens AB (publ) INTERIM REPORT JULY – SEPTEMBER 2026Spermosens reported Q3 2026 operating loss of SEK 2.377 million and net sales of SEK 0, with cash and cash equivalents of SEK 4.026 million. The company raised SEK 4.85 million and signed a collaboration with Genea to run an independent clinical study of JUNO-Checked, with the study expected to start next year.MarketScreenerSpermosens to present JUNO-Checked at fertility congress in the USSpermosens will present its JUNO-Checked system at the ASRM 2026 fertility congress in Baltimore on October 24-27. The system measures sperm-JUNO receptor binding, currently under clinical validation at a Malmo center. The company plans to commercialize via licensing or co-development agreements.news.cision.comBulletin from Extraordinary General Meeting in Spermosens AB (publ)Spermosens AB's extraordinary general meeting on September 1, 2026, unanimously approved a directed issue of up to 24,096,384 units to Duvold Holding ApS and Ulrik Spork, with deviation from pre-emption rights. The subscription price is SEK 0.0083 per unit, a 15% discount to VWAP, and proceeds total up to SEK 0.2 million.news.cision.comSpermosens AB (publ) to Host Live Q&A Webcast on 27 August 2026Spermosens AB will host a live Q&A webcast on 27 August 2026 at 12:00 CET, with CEO Tore Duvold addressing questions. The session follows the Q2 2026 report and is open to all interested parties, with questions due by 26 August.news.cision.comSpermosens AB (publ) INTERIM REPORT APRIL – JUNE 2026Spermosens reported Q2 2026 results with recruitment of 44 patients into its JUNO-Checked Generation 3 clinical validation study, exceeding expectations. The company secured a SEK 4.85 million capital facility and plans to complete the study by year-end. It also expanded partner discussions and presented results at ESHRE.news.cision.comKallelse till extra bolagsstämma i Spermosens AB (publ)Spermosens AB called an extraordinary shareholders' meeting on 1 September 2026 to approve a rights issue. The board proposes issuing up to 24,096,384 units at 0.0083 SEK each, with a 15% discount to VWAP, to raise up to 199,999.9872 SEK. The issue is part of a capital facility to fund clinical validation of JUNO-Checked Generation 3.news.cision.comSpermosens raises approx. SEK 4.85m in directed issue and calls EGMSpermosens' board resolved a directed issue of up to 560.24 million units at SEK 0.0083 each, raising about SEK 4.65 million, and called an EGM for a second issue of up to 24.1 million units. The total gross proceeds are about SEK 4.85 million, with a 15% discount to VWAP. The EGM is planned for 1 September 2026.news.cision.comNotice of Extraordinary General Meeting in Spermosens AB (publ)Spermosens AB will hold an extraordinary general meeting on 1 September 2026 to approve a directed issue of up to 24,096,384 units, each comprising a share and a warrant, with deviation from shareholders' pre-emption rights. The issue, part of a Capital Facility, raises up to SEK 199,999.9872 and is directed to Duvold Holding ApS and Ulrik Spork.news.cision.comSpermosens calls SEK 4.85 million under previously announced Capital FacilitySpermosens' board resolved to call the full SEK 4.85 million under its capital facility, approved on 18 June 2026. The capital will be issued as units, each with one share and one warrant, with a 15% discount to the VWAP. A measurement period and proposed extraordinary general meeting follow.